Meeting
2023 ASCO Annual Meeting
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).
Authors
Patrick M. Forde
Bloomberg–Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
Patrick M. Forde , Anna K. Nowak , Brett Gordon Maxwell Hughes , Peey Sei Kok , Chris Brown , Zhuoxin Sun , Valsamo Anagnostou , Ken O'Byrne , Sonia Yip , Alistair Cook , Willem Joost Lesterhuis , Nick Pavlakis , Julie R. Brahmer , Hedy L. Kindler , Anne S. Tsao , Marjorie Glass Zauderer , Suresh S. Ramalingam , Martin R. Stockler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Clinical Trial Registration Number
NCT04334759
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8599)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8599
Abstract #
TPS8599
Poster Bd #
226a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.
First Author: Patrick M. Forde
Poster
2021 ASCO Annual Meeting
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.
First Author: Patrick M. Forde
Poster
2017 ASCO Annual Meeting
Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.
First Author: Gerard Zalcman
Poster
2022 ASCO Annual Meeting
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
First Author: Luis G. Paz-Ares